Pay in 4 interest-free payments of $6.38 Learn more
Ships within 48 hours · Estimated delivery Oct 29 - Nov 3
An innovator files a CP raising scientific or regulatory concerns about a competitors pending approval questions about bioequivalence methodology, manufacturing controls, formulation characterization, or potential safety signals
As the market becomes more receptive to the concept of metabolic wellness and the emerging opportunity for biosimilar production, there is likely to be a positive impact on affordability and increased access to the market
Glucagon-like peptide-1 receptor agonist use and renal impairment: a retrospective analysis of an electronic health records database in the U.S
Recent sales of a little-known stock, Madrigal Pharmaceuticals (NASDAQ: MDGL), could bode well for Novo Nordisk A/S (NYSE: NVO)
Long B, Pelletier J, Koyfman A, Bridwell RE
US$ 22.04
US$ 29.73
US$ 27.61
US$ 24.92
US$ 25.04
US$ 28.15
US$ 20.78
